Donald Washburn - Amedisys Non-Executive Co-Chairman of the Board

AMED Stock  USD 91.16  0.08  0.09%   

Chairman

Mr. Donald A. Washburn is NonExecutive Lead Independent Chairman of the Board of the Amedisys, Inc. Mr. Washburn, a private investor for over 20 years, currently serves as a director on the boards of the following publicly traded companies LaSalle Hotel Properties, a real estate investment trust The Greenbrier Companies, Inc., a manufacturer and lessor of rail cars and barges and Key Technology, Inc., which designs and manufactures process automation systems for the food processing and industrial markets. He has also served on multiple private company boards. He also is a retired Executive Vice President of Northwest Airlines, Inc. and was the Chairman and PresidentNorthwest Cargo, Inc. Prior to joining Northwest Airlines, Inc., Mr. Washburn was a corporate Senior Vice President of Marriott Corporationrationration, most recently Executive Vice President and general manager of its Courtyard Hotel division. Mr. Washburn has served as the NonExecutive Chairman of our Board of Directors since August 31, 2014. From February 20, 2014 to August 31, 2014, Mr. Washburn served as NonExecutive CoChairman of our Board of Directors. From November 2011 until his appointment as NonExecutive CoChairman of our Board of Directors, he served as our independent Lead Director. since 2014.
Age 73
Tenure 10 years
Address 3854 American Way, Baton Rouge, LA, United States, 70816
Phone225 292 2031
Webhttps://www.amedisys.com

Donald Washburn Latest Insider Activity

Tracking and analyzing the buying and selling activities of Donald Washburn against Amedisys stock is an integral part of due diligence when investing in Amedisys. Donald Washburn insider activity provides valuable insight into whether Amedisys is net buyers or sellers over its current business cycle. Note, Amedisys insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amedisys'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Amedisys Management Efficiency

The company has return on total asset (ROA) of 0.0598 % which means that it generated a profit of $0.0598 on every $100 spent on assets. This is way below average. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.13, whereas Return On Tangible Assets are projected to grow to (0.01). At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 24 M, whereas Intangible Assets are forecasted to decline to about 64.1 M.
The company currently holds 487.21 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Amedisys has a current ratio of 1.04, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Amedisys until it has trouble settling it off, either with new capital or with free cash flow. So, Amedisys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amedisys sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amedisys to invest in growth at high rates of return. When we think about Amedisys' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CHAIRMAN Age

Joey JacobsAcadia Healthcare
63
Robert AdamsNational HealthCare
72
Wayne DeVeydtSurgery Partners
54
Alan MillerUniversal Health Services
86
Christopher LaitalaSurgery Partners
42
Henry EsberInnovAge Holding Corp
78
Roy ChristensenThe Ensign Group
84
Bruce ShearAcadia Healthcare
62
Daniel McCartneyHealthcare Services Group
63
Mark HeaneyAddus HomeCare
58
Leo HigdonEncompass Health Corp
74
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people. Amedisys (AMED) is traded on NASDAQ Exchange in USA. It is located in 3854 American Way, Baton Rouge, LA, United States, 70816 and employs 19,000 people. Amedisys is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Amedisys Leadership Team

Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel Mccoy, COO
Christopher Gerard, COO
Michael North, Senior Vice President - Operations
Larry Pernosky, Chief Human Resource Officer
Janet Britt, VP Collections
Richard Ashworth, CEO President
Scott Ginn, Chief Accounting Officer
Jeffrey Rideout, Director
Nick Muscato, Vice President of Strategic Finance
David Kemmerly, Senior Vice President - Government Affairs
Lawrence Pernosky, Chief Human Resource Officer
Nathaniel Zilkha, Director
Adam Holton, Chief Officer
Bruce Perkins, Independent Director
Susan Sender, Chief Clinical Operations Officer
Stephen Seim, Chief Strategy Officer
John Nugent, Chief Officer
Pete Hartley, CTO Systems
Kendra Kimmons, VP Relations
Donald Washburn, Non-Executive Co-Chairman of the Board
Jeffrey Jeter, Chief Compliance Officer
Martin Howard, CIO
Jennifer Griffin, Deputy VP
Jane Carmody, Chief Clinical Operations Officer
Sharon Brunecz, Chief Human Resource Officer
Ronald LaBorde, Vice Chairman and CFO
Allyson Guidroz, Chief Officer
Linda Hall, Independent Director
Julie Klapstein, Director
Denise Bohnert, Chief Officer
Paul Kusserow, CEO and President and Director
David Pearce, Chief Compliance Officer
Jake Netterville, Independent Director
Dan McCoy, COO
Gary Willis, CFO
Richard Lechleiter, Director
David Castille, IR Contact Officer, Director, Treasury/Finance

Amedisys Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amedisys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amedisys' short interest history, or implied volatility extrapolated from Amedisys options trading.

Pair Trading with Amedisys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amedisys Stock

  0.71JNJ Johnson Johnson Aggressive PushPairCorr

Moving against Amedisys Stock

  0.84XOM Exxon Mobil Corp Earnings Call TomorrowPairCorr
  0.83CAT Caterpillar Earnings Call TodayPairCorr
  0.8AXP American Express Financial Report 19th of July 2024 PairCorr
  0.78BAC Bank of America Sell-off TrendPairCorr
  0.76CVX Chevron Corp Earnings Call TomorrowPairCorr
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.40)
Earnings Share
(0.30)
Revenue Per Share
68.603
Quarterly Revenue Growth
0.016
Return On Assets
0.0598
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.